| Systematic (IUPAC) name | |
|---|---|
| N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | IV |
| Identifiers | |
| CAS number | 110230-98-3 220201-34-3 (sodium salt) |
| ATC code | None |
| PubChem | CID 5486799 |
| UNII | P4ROX5ELT2 |
| Chemical data | |
| Formula | C38H41N5O9 |
| Mol. mass | 711.76 g/mol |
| SMILES | eMolecules & PubChem |
| (what is this?) (verify) |
|
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664nm normally provided by a laser tuned to this wavelength.[1]
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]
It is trademarked as Aptocine by Light Sciences Oncology.[3]